ABUS
Price
$2.08
Change
+$0.02 (+0.97%)
Updated
Dec 7, 6:59 PM EST
83 days until earnings call
ARRY
Price
$15.88
Change
+$0.06 (+0.38%)
Updated
Dec 7, 6:59 PM EST
88 days until earnings call
Ad is loading...

ABUS vs ARRY ᐉ Comparison: Which is Better to Invest?

Header iconABUS vs ARRY Comparison
Open Charts ABUS vs ARRYBanner chart's image
Arbutus Biopharma
Price$2.08
Change+$0.02 (+0.97%)
Volume$231.04K
CapitalizationN/A
Array Technologies
Price$15.88
Change+$0.06 (+0.38%)
Volume$2.08M
CapitalizationN/A
View a ticker or compare two or three
ABUS vs ARRY Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ABUS vs. ARRY commentary
Dec 08, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a StrongBuy and ARRY is a StrongSell.

COMPARISON
Comparison
Dec 08, 2023
Stock price -- (ABUS: $2.08 vs. ARRY: $15.88)
Brand notoriety: ABUS and ARRY are both not notable
ABUS represents the Biotechnology, while ARRY is part of the Electrical Products industry
Current volume relative to the 65-day Moving Average: ABUS: 53% vs. ARRY: 38%
Market capitalization -- ABUS: $308.56M vs. ARRY: $2.23B
ABUS [@Biotechnology] is valued at $308.56M. ARRY’s [@Electrical Products] market capitalization is $2.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The market cap for tickers in the [@Electrical Products] industry ranges from $181.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B. The average market capitalization across the [@Electrical Products] industry is $3.79B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileARRY’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • ARRY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABUS is a better buy in the long-term than ARRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while ARRY’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 4 bearish.
  • ARRY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than ARRY.

Price Growth

ABUS (@Biotechnology) experienced а +1.22% price change this week, while ARRY (@Electrical Products) price change was +2.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10152.36%. For the same industry, the average monthly price growth was +6.66%, and the average quarterly price growth was +25.39%.

The average weekly price growth across all stocks in the @Electrical Products industry was +1.39%. For the same industry, the average monthly price growth was -0.73%, and the average quarterly price growth was -21.23%.

Reported Earning Dates

ABUS is expected to report earnings on Feb 29, 2024.

ARRY is expected to report earnings on Mar 05, 2024.

Industries' Descriptions

@Biotechnology (+10152.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Electrical Products (+1.39% weekly)

The industry produces a diverse range of electricity-powered equipment, appliances and components, catering to both households and industries. The products include power, distribution and specialty transformers; electric motors, generators and motor-generator sets; switchgear and switchboard apparatus; light bulbs, tubes, fittings and electric signs etc. Consumer income, construction spending, and industrial production are major drivers of demand for this industry’s products. Large companies tend to have economies of scale in production, marketing, and distribution, while smaller companies can potentially carve out their own market through niche or specialty offerings. The US electrical products manufacturing industry includes about 5,700 establishments (single-location companies and units of multi-location companies) with combined annual revenue of about $125 billion. (according to a study published in First Research). Emerson Electric Co., Hubbell Incorporated and Eaton Corporation plc are major electrical products makers in the U.S.

SUMMARIES
A.I.dvisor published
a Summary for ABUS with price predictions.
OPEN
A.I.dvisor published
a Summary for ARRY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARRY($2.23B) has a higher market cap than ABUS($309M). ABUS YTD gains are higher at: -10.944 vs. ARRY (-17.848). ARRY has higher annual earnings (EBITDA): 275M vs. ABUS (-73.39M). ARRY has more cash in the bank: 174M vs. ABUS (134M). ABUS has less debt than ARRY: ABUS (1.91M) vs ARRY (698M). ARRY has higher revenues than ABUS: ARRY (1.64B) vs ABUS (22.2M).
ABUSARRYABUS / ARRY
Capitalization309M2.23B14%
EBITDA-73.39M275M-27%
Gain YTD-10.944-17.84861%
P/E RatioN/A38.17-
Revenue22.2M1.64B1%
Total Cash134M174M77%
Total Debt1.91M698M0%
FUNDAMENTALS RATINGS
ABUS vs ARRY: Fundamental Ratings
ABUS
ARRY
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9728
PRICE GROWTH RATING
1..100
5679
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (46) in the Biotechnology industry is in the same range as ARRY (70). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.

ARRY's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as ABUS (100). This means that ARRY’s stock grew similarly to ABUS’s over the last 12 months.

ARRY's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for ABUS (97). This means that ARRY’s stock grew significantly faster than ABUS’s over the last 12 months.

ABUS's Price Growth Rating (56) in the Biotechnology industry is in the same range as ARRY (79). This means that ABUS’s stock grew similarly to ARRY’s over the last 12 months.

ARRY's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ABUS (100). This means that ARRY’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSARRY
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 7 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
82%
Bearish Trend 11 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
76%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBCIX16.780.09
+0.54%
Gabelli Dividend Growth I
JFEAX13.320.06
+0.45%
JPMorgan Developed International Value A
MYINX6.99N/A
N/A
MainStay WMC Intl Research Eq Inv
DWOIX15.60N/A
N/A
BNY Mellon Research Growth I
JANIX24.11-1.70
-6.59%
Janus Henderson Triton D